Body composition and the skeletal muscle compartment in liver transplantation: Turning challenges into opportunities.
body composition
liver disease
liver transplantation
myosteatosis
sarcopenia
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
26
04
2022
received:
17
01
2022
accepted:
03
05
2022
pubmed:
7
5
2022
medline:
5
8
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Frailty, nutritional status, and body composition are increasingly under the spotlight of interest in various clinical scenarios including liver transplantation. To address the rapidly accumulating evidence in this field, recent European and North American practice guidelines have clearly underlined the clinical importance of nutritional status and body composition with adopting their assessment in patients with liver disease and in transplant candidates into their recommendations. While earlier reports, and therefore present guidelines, were focusing predominantly on quantitative alterations of the skeletal muscle mass (sarcopenia), recent studies have identified qualitative alterations such as intramuscular fat accumulation (myosteatosis) and sarcopenic obesity as emerging risk factors for poor clinical outcomes. In this review, the role of body composition in the context of liver transplantation will be discussed with a focus on the skeletal muscle compartment. A brief overview of current assessment modalities including their limitations, diagnostic challenges, prognostic significance, and pathophysiology are included. Possibilities to incorporate body composition parameters into clinical decision making are discussed. In addition, novel trends and remaining challenges in the therapeutic targeting of body composition and the skeletal muscle compartment are highlighted.
Identifiants
pubmed: 35523584
doi: 10.1111/ajt.17089
pii: S1600-6135(22)00023-5
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1943-1957Informations de copyright
© 2022 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Czigany Z, Kramp W, Bednarsch J, et al. Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation. Am J Transplant. 2019;20(2):493-503.
Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512-514.
Traub J, Bergheim I, Eibisberger M, Stadlbauer V. Sarcopenia and liver cirrhosis-comparison of the European working group on sarcopenia criteria 2010 and 2019. Nutrients. 2020;12(2):547.
Meister F, Luje G, Verhoeven S, et al. The role of sarcopenia and myosteatosis in short- and long-term outcomes following curative-intent surgery for hepatocellular carcinoma in a European cohort. Cancers. 2022;14(3):720.
Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int. 2019;13(6):674-687.
van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JNM. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant. 2016;16(8):2277-2292.
Nachit M, Leclercq IA. Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms! Clin Sci. 2019;133(3):465-481.
Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis-the confluence of 2 prognostic titans. Liver Int. 2018;38(10):1706-1717.
Nam NH, Kaido T, Uemoto S. Assessment and significance of sarcopenia in liver transplantation. Clin Transpl. 2019;33(12). doi: 10.1111/ctr.13741
Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci. 2020;21(15):5357.
Ebadi M, Bhanji RA, Tandon P, Mazurak V, Baracos VE, Montano-Loza AJ. Review article: prognostic significance of body composition abnormalities in patients with cirrhosis. Aliment Pharmacol Ther. 2020;52(4):600-618.
Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2021;76:588-599.
EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172-193.
Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr. 2020;39(12):3533-3562.
Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatol. 2021;74(3):1611-1644.
Carey EJ, Lai JC, Sonnenday C, et al. A north American expert opinion statement on sarcopenia in liver transplantation. Hepatol. 2019;70(5):1816-1829.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed). 2008;336(7650):924-926.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol. 2018;67(1):328-357.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412-423.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
Buchard B, Boirie Y, Cassagnes L, Lamblin G, Coilly A, Abergel A. Assessment of malnutrition, sarcopenia and frailty in patients with cirrhosis: which tools should we use in clinical practice? Nutrients. 2020;12(1):186.
Bhanji RA, Takahashi N, Moynagh MR, et al. The evolution and impact of sarcopenia pre- and post-liver transplantation. Aliment Pharmacol Ther. 2019;49:807-813.
Lee CM, Kang BK, Kim M. Radiologic definition of sarcopenia in chronic liver disease. Life (Basel). 2021;11(2):86.
Tandon P, Mourtzakis M, Low G, et al. Comparing the variability between measurements for sarcopenia using magnetic resonance imaging and computed tomography imaging. Am J Transplant. 2016;16(9):2766-2767.
Surov A, Paul L, Meyer HJ, Schob S, Engelmann C, Wienke A. Apparent diffusion coefficient is a novel imaging biomarker of myopathic changes in liver cirrhosis. J Clin Med. 2018;7(10):359.
Paris MT, Tandon P, Heyland DK, et al. Automated body composition analysis of clinically acquired computed tomography scans using neural networks. Clin Nutr. 2020;39(10):3049-3055.
Nowak S, Theis M, Wichtmann BD, et al. End-to-end automated body composition analyses with integrated quality control for opportunistic assessment of sarcopenia in CT. Eur Radiol. 2021;32:3142-3151.
Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl. 2017;23(5):625-633.
Engelmann C, Schob S, Nonnenmacher I, et al. Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. Aliment Pharmacol Ther. 2018;48(11-12):1271-1281.
Meister FA, Bednarsch J, Amygdalos I, et al. Various myosteatosis selection criteria and their value in the assessment of short- and long-term outcomes following liver transplantation. Sci Rep. 2021;11(1):13368.
Nachit M, Kwanten WJ, Thissen JP, et al. Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity. J Hepatol. 2021;75(2):292-301.
Czigany Z, Kramp W, Lurje I, et al. The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation. J Cachexia Sarcopenia Muscle. 2021;12:358-367.
Irwin NEA, Fabian J, Hari KR, Lorentz L, Mahomed A, Botha JF. Myosteatosis, the more significant predictor of outcome: an analysis of the impact of Myosteatosis, sarcopenia, and sarcopenic obesity on liver transplant outcomes in Johannesburg, South Africa. Exp Clin Transplant. 2021;19(9):948-955.
Nachit M, De Rudder M, Thissen JP, et al. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia Sarcopenia Muscle. 2021;12(1):144-158.
Lai Q, Magistri P, Lionetti R, et al. Sarco-model: a score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation. Liver Int. 2021;41(7):1629-1640.
van Vugt JLA, Alferink LJM, Buettner S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol. 2018;68(4):707-714.
Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019;54(10):845-859.
Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021;75(Suppl 1):S49-s66.
Dunn MA, Rogal SS, Duarte-Rojo A, Lai JC. Physical function, physical activity, and quality of life after liver transplantation. Liver Transplant. 2020;26(5):702-708.
Brustia R, Monsel A, Skurzak S, et al. Guidelines for perioperative care for liver transplantation: enhanced recovery after surgery (ERAS) recommendations. Transplant. 2022;106(3):552-561.
Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013;13(6):1549-1556.
Ebadi M, Tsien C, Bhanji RA, et al. Myosteatosis in cirrhosis: a review of diagnosis, pathophysiological mechanisms and potential interventions. Cell. 2022;11(7):1216.
Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatol. 2017;65(6):2045-2058.
Deng N, Mallepally N, Peng FB, Kanji A, Marcelli M, Hernaez R. Serum testosterone levels and testosterone supplementation in cirrhosis: a systematic review. Liver Int. 2021;41(10):2358-2370.
Feike Y, Zhijie L, Wei C. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton). 2021;4(3):221-233.
Rosenberg IH. Summary comments. Am J Clin Nutr. 1989;50(5):1231-1233.